Joint Formulary & PAD

Ciclosporin - Allergic conjunctivitis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Eye drops (unit dose)
Associated Icons :
SPC
Restrictions / Comments :
Important

0.1% ciclosporin (Verkazia

Prescribe by brand for Vernal Keratoconjunctivitis (VKC) to ensure licensed product for this indication is dispensed.

The specialist team will initiate and prescribe for at least 3 months until the VKC is stabilised, prior to transfer of care

PAD Profile

ChemicalSubstance :
Ciclosporin
Indication :
Allergic conjunctivitis
Group Name :
Keywords :
severe vernal keratoconjunctivitis, keratitis
Brand Names Include :
Verkazia
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
1

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed to add Verkazia® (ciclosporin 1mg/mL eye drops) for the treatment of Vernal Keratoconjunctivitis (VKC) to the Joint Formulary for children aged over 4 and adolescents.

Verkazia® (ciclosporin 1mg/mL eye drops) single unit dose vials should be prescribed by brand for VKC to ensure the patient is dispensed the ciclosporin preparation licensed for this indication.

A BLUE (with specialist team initiation) traffic light status was agreed with the specialists prescribing for 3 months or until the patients condition is stabilised, prior to transfer of care